Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:37:50.313Z.
Calculation as of: 2026-10-06T16:37:50.313Z.
Quote observation: 2026-10-06T16:34:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a560454fa7ec99f8e1b664e45bbeeb036d535f564db40397f61edcd9a9056247
PE RATIO
N/A
Market Cap
$4.53M
PE Ratio
N/A
TTM Avg
79.42
3Y Avg
79.42
5Y Avg
79.42
Market Cap
$5.20M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $4.77M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.64M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.63M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.52M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.53M | N/A | 79.42 | 79.42 | 79.42 |
| Imunon, Inc. (IMNN)vs › | $5.02M | N/A | 1.64 | 1.64 | 1.64 |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.38M | N/A | 1.25 | 1.25 | 1.25 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.20M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.23M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.88
Forward EPS (Est.)
$-4.65
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
